WASOG Clinical Trial Endpoint Task Force: Executive Summary

Over the past few years, an increased number of clinical trials have been performed evaluating specific therapies for pulmonary and cardiac sarcoidosis. However, a lack of consensus remains for appropriate clinical trial endpoints. In 2024, the World Association of Sarcoidosis and Other Granulomatous disease (WASOG) established a clinical trial endpoint Task Force to update the 2011 WASOG Task Force. This initiative was spearheaded by five sarcoidosis specialists (RPB, EEL, DAC, MAJ, AUW) and enlisted a total of 55 stakeholders, including 37 health care providers, 14 industry representatives, and 4 patients. In March 2025, 46 stakeholders participated in a one-day meeting which included twenty focused talks regarding clinical trial endpoints for pulmonary and cardiac sarcoidosis trials. A compilation of individual talk summaries was prepared and distributed to all stakeholders, including those unable to attend the meeting. Based on feedback from all stakeholders, the team leaders developed a series of statements reflecting the presentations and discussions with subsequent anonymous voting by all stakeholders. The majority of the voters endorsed thirteen specific clinical trial endpoint statements: two evaluating overall trial design, seven regarding pulmonary sarcoidosis, and four discussing cardiac sarcoidosis.